BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,182,617 shares of the biotechnology company’s stock after selling 155,445 shares during the quarter. Fisher Asset Management LLC owned approximately 1.54% of BioCryst Pharmaceuticals worth $23,933,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after acquiring an additional 127,708 shares during the last quarter. Two Sigma Advisers LP boosted its position in BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after acquiring an additional 261,500 shares during the last quarter. FMR LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 3rd quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after purchasing an additional 46,110 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company’s stock valued at $14,349,000 after purchasing an additional 102,860 shares during the last quarter. Finally, PDT Partners LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 42.4% in the 3rd quarter. PDT Partners LLC now owns 522,280 shares of the biotechnology company’s stock valued at $3,969,000 after purchasing an additional 155,510 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BCRX. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price target (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Down 0.8 %

NASDAQ:BCRX opened at $8.54 on Tuesday. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -14.00 and a beta of 1.75. The firm’s fifty day simple moving average is $8.11 and its 200 day simple moving average is $7.86. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The company’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 EPS. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.